Chromosomal aberration frequency in peripheral lymphocytes of healthy individuals has been found to be predictive of future cancer risk. The variability of chromosomal aberrations over time, which is largely unknown, should be clarified to interpret the strength of this association and to determine its use in cancer prediction. Intra-and interindividual variability in chromosomal aberration frequency was therefore determined. From a pooled database comprising 11 national cohorts , the authors included 9,433 blood samples from 3,550 subjects with at least one repeated chromosomal aberration measurement. The generalized concordance correlation coefficient of 0.19 was low, indicating high intraindividual variability compared with interindividual variability, resulting in a high likelihood of misclassification. The relation between chromosomal aberration frequency and future cancer risk has probably been underestimated in previous studies. A single chromosomal aberration measurement seems not to be representative of the whole lifespan level of chromosome instability and greatly limits the use of chromosomal aberration frequency-as measured with Giemsa staining-for individual risk assessment.
Chromosomal aberration frequency in peripheral lymphocytes (shown by Giemsa staining and scored according to Savage's classification (1)) has been found to predict future cancer incidence in several epidemiologic studies (2) (3) (4) (5) (6) . A recent pooled analysis of these studies largely confirmed previous observations (7) . The risk of cancer was increased for subjects in the medium (relative risk ¼ 1.31, 95% confidence interval (CI): 1.07, 1.60) and high (relative risk ¼ 1.41, 95% CI: 1.16, 1.72) tertiles of chromosomal aberration frequency compared with the low. To take into account interlaboratory variation, we standardized single counts according to the percentile distribution of chromosomal aberration counts within each laboratory (7) . Only one chromosomal aberration count was available for most subjects, which was assumed to be valid for classifying subjects over time (8) . However, variability in chromosomal aberration frequency between subjects and over time may have led to misclassification. Random error in the predictor variable is known to generally bias risks toward the null value (9) . Given the rising interest in using validated biomarkers for (individual) cancer risk assessment, the present analyses aimed at investigating the extent of agreement for repeated chromosomal aberration frequency measurements over time and assessing potential effects on reported exposure-response relations.
MATERIALS AND METHODS
We used the same data set as analyzed for the pooled analysis published by Bonassi et al. (7) in 2008, including data collected in chromosomal aberration surveys performed during 1965-2002 on over 20,000 subjects (7) . For inclusion in the analysis, at least 2 measurements per subject had to be available (time between tests at least 6 months and at most 10 years). Subjects with more than 10 repeated measurements were excluded because of possible specific reasons for performing a chromosomal aberration test (e.g., an exposure incident). For the remaining subjects, the first 4 measurements (if available) were included in statistical analyses in order to keep the data set more balanced. Chromosomal aberration counting had been performed in 25 different laboratories in Croatia, the Czech Republic, Hungary, Italy, Lithuania, and Slovakia (2-5, 10, 11) . For each test, demographic data on the subject, information on exposure to genotoxic agents, smoking habits, and details of the chromosomal aberration counting procedure (test date, culture time, and number of metaphases scored) were abstracted. Chromosomal aberration frequency was defined as the number of cells with aberrations, excluding gaps, per 100 cells (2) . At least 50 metaphases had to be scored from each sample.
The intraclass correlation coefficient (12) and generalized concordance correlation coefficient (qCCC (13) ) are often used to measure agreement for data on a continuous scale (14) . Recently, the qCCC has been generalized to other distributions in the exponential family, including the Poisson and negative binomial distribution (15) . The definition of qCCC is as follows:
where i indexes subjects, and j and k index observers or measurement occasions and can be estimated by using generalized linear mixed models (16) . We calculated qCCC on the basis of estimated random effects variances for subjects and laboratories, while intraindividual variation in chromosomal aberration frequency was modeled by using a negative binomial distribution. Estimation was performed through a Bayesian generalized linear mixed model as implemented in the free software BayesX. More details are provided in the Web Appendix, which is posted on the Journal's Web site (http://aje.oxfordjournals.org/). The same model was used to assess the effects of subject and test characteristics on the chromosomal aberration frequency.
RESULTS AND DISCUSSION
A total of 9,433 blood samples from 3,550 individuals was included, with on average 1.9 years (10th-90th percentile: 0.7-4.0) between tests. Table 1 provides descriptors of chromosomal aberration frequencies stratified by demographic and test characteristics, as well as overall and stratumspecific qCCCs. Because qCCCs result from the ratio of inter-to intraindividual variability, the low overall qCCC of 0.19 indicates that the intraindividual variability is the major source of variability in chromosomal aberration frequency. Estimated qCCCs vary, however, across the strata. The qCCC of 0.79 was, for example, much higher in the small group exposed to biologic agents, suggesting a higher interindividual variability in chromosomal aberration frequency in this group. Note that a considerable part of the variability in chromosomal aberration frequency is due to the limited number of metaphases scored. As illustrated in the online material, the qCCC of <0.6 is low even in the absence of ''real'' intraindividual variability when the number of assessed metaphases is below 400.
In addition, we compared classification in chromosomal aberration tertiles based on the first and second chromosomal aberration measurement to assess potential misclassification. The classification in tertiles on the basis of the first measurement was the exposure metric used in the aforementioned epidemiologic studies. Crude agreement between these classifications (low-medium-high) was 44%, with a weighted kappa of 0.18 (data not shown). This is consistent with the low overall qCCC as calculated from the statistical model and implies substantial misclassification. Consequently, the reported dose-response relation between chromosomal aberration tertiles and cancer risk may have been seriously attenuated.
Vral et al. (17) also reported high intraindividual variability in chromosomal aberration (measured by the micronucleus and G 2 assay), and they suggested that repeated blood sampling might be necessary to allow more reliable classification of individuals. Our findings indicate that, in addition to repeated sampling, increasing the number of scored metaphases is important.
In conclusion, the slope of dose-response relations between blood chromosomal aberration frequencies and cancer risk found in earlier studies has probably been underestimated, and the low qCCC may have contributed to the limited power of cancer-specific analyses. Results from a nested casecontrol study performed within a subset of the European pooled data set are consistent with this hypothesis, because the odds ratio for an association between chromosomal aberration tertile and cancer risk peaked at 9.40 (95% CI: 2.6, 28.0) in a group of slides homogeneously prepared and scored (18) . In addition, the current study identified 2 major limitations of chromosomal aberration frequency measurement by Giemsa staining as the predictor of (individual) risk of cancer (i.e., the high intraindividual and sampling variance as a result of the small number of metaphases counted).
Although epidemiologic results have lent support to the possible use of biomarkers of chromosomal instability in cancer risk assessment, the use of chromosomal aberration frequency in healthy subjects seems of limited value for prediction of individual cancer risk. Therefore, efforts to apply biomarkers of chromosomal instability to individual cancer risk assessment should focus on new cytogenetic techniques where large numbers of cells/metaphases can be counted (e.g., lab-on-a-chip fluorescent in situ hybridization techniques or virtual karyotyping). Susan Peters and Dr. Lützen Portengen are equal first authors.
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